Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

Domvri, Kalliopi; Bougiouklis, Dimitrios; Porpodis, Κonstantinos; Xristoforidis, Manolis; Liaka, Alexandra; Eleutheriadou, Ellada; Lampaki, Sofia; Lazaridis, George; Organtzis, John; Kyriazis, George A.; Hohenforst-Schmidt, Wolfgang; Tsirgogianni, Katerina; Karavasilis, Vasilios; Baka, Sofia; Darwiche, Kaid; Freitag, Lutz; Trakada, Georgia; Zarogoulidis, Konstantinos

doi:10.7150/jca.11308

Cited by 11 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis of SCLC remains extremely poor mainly for recurrence and chemoresistance, but the mechanism of chemoresistance is still unclear 20 . It has been reported that lncRNAs were involved in anticancer drug resistance 19 , 21 – 25 .…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a

Sun

Wang

et al. 2018

Cell Death Dis

View full text Add to dashboard Cite

Despite progress in treatment of small cell lung cancer (SCLC), its multidrug chemoresistance and poor prognosis still remain. Recently, we globally assessed long non-coding RNAs (lncRNAs) for contributions to SCLC chemoresistance using microarray data, in vitro and in vivo assays. Here we reported that HOTTIP, encoding a lncRNA that is frequently amplified in SCLC, was associated with SCLC cell chemosensitivity, proliferation, and poor prognosis of SCLC patients. Moreover, mechanistic investigations showed that HOTTIP functioned as an oncogene in SCLC progression by binding miR-216a and abrogating its tumor-suppressive function in this setting. On the other hand, HOTTIP increased the expression of anti-apoptotic factor BCL-2, another important target gene of miR-216a, and jointly enhanced chemoresistance of SCLC by regulating BCL-2. Taken together, our study established a role for HOTTIP in SCLC progression and chemoresistance suggest its candidacy as a new diagnostic and prognostic biomarker for clinical management of SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a

Sun

Wang

et al. 2018

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…Since somatostatin is able to exert antiproliferative effects and reduce tumor growth by suppressing the synthesis and secretion of growth factors, including IgF-1, an important modulator of many neoplasms, 38,39 we measured IgF-1 levels before and after treatment, without nonetheless finding any statistically significant impact on patients’ survival.…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis

Boutsikou

Porpodis

Chatzipavlidou

et al. 2019

Technol Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Background: Νeuroendocrine tumors of the lungs are rare arising in the thymus and gastro-entero-pancreatic tract and belonging to foregut of neuroendocrine tumors. The aim of the present prospective study was to estimate the potential impact of single-photon emission computed tomography somatostatin receptor scintigraphy using 99mTc-Tektrotyd on diagnosis, treatment response, and prognosis in patients with neuroendocrine tumors of the lungs. Methods: Thirty-six patients with neuroendocrine tumors of the lungs were evaluated by using 99mTc-HYNIC-TOC scintigraphy. The scintigraphic results were compared to liver tissue uptake (Krenning score). Likewise, the functional imaging results were compared with biochemical indices including chromogranin A, neuroendocrine-specific enolase, and insulin-like growth factor 1 at the time of diagnosis (baseline) and disease progression. Results: The number of somatostatin receptors, expressed with Krenning score, did not show any correlation with the survival of patients both at baseline ( P = .08) and at disease progression ( P = .24), and scintigraphy results did not relate significantly to progression-free survival. Comparing the results of 99mTc-HYNIC-TOC scintigraphy according to the response of patients in the initial treatment, a statistically significant negative correlation was observed both in the first and in the second scintigraphy with patients’ response ( P = .001 and P < .001, respectively). The concentrations of biochemical markers were in accordance with scintigraphy results in the diagnosis. Conclusion: This study indicates that 99mTc-HYNIC-TOC scintigraphy appears to be a reliable, noninvasive technique for detection of primary neuroendocrine tumors and their locoregional or distant metastases, although it cannot be used as a neuroendocrine tumors of the lungs predictive technique.

show abstract

“… 12 Regarding SCLC chemotherapy is still the considered the best first line treatment, however; several novel therapies are being investigated. 13 - 16 The role of tyrosine kinase inhibitors as neo-adjuvant or adjuvant treatment is still under investigation. One observation has to be taken into serious consideration that if chemotherapy is administered in EGFR positive patients as neo-adjuvant treatment then the mutation status will change along with the gene status of several other involved pathways with an unknown treatment effect in the future if treatment will become necessary (disease relapse).…”

Section: Introductionmentioning

confidence: 99%

Tyrosine Kinase Inhibitors for the Elderly

Hohenforst-Schmidt¹,

Steinheimer²,

Benhassen³

et al. 2016

J. Cancer

Self Cite

View full text Add to dashboard Cite

Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient. The side effects of these agents are still severe for several patients. In the recent years further investigation of the cancer genome has led to targeted therapies. There have been numerous publications regarding novel agents such as; erlotinib, gefitinib and afatinib. In specific populations these agents have demonstrated higher efficiency and this observation is explained by the overexpression of the EGFR pathway in these populations. We suggest that TKIs should administered in the elderly, and with the word elderly we propose the age of 75. The treating medical doctor has to evaluate the performance status of a patient and decide the best treatment in several cases indifferent of the age. TKIs in most studies presented safety and efficiency and of course dose modification should be made when necessary. Comorbidities should be considered in any case especially in this group of patients and the treating physician should act accordingly.

show abstract

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?

Cited by 11 publications

References 27 publications

Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a

Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a

Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis

Tyrosine Kinase Inhibitors for the Elderly

Contact Info

Product

Resources

About